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Protein biopharmaceuticals are highly successful, but their utility is compromised by their
propensity to aggregate during manufacture and storage. As aggregation can be triggered by
non-native states, whose population is not necessarily related to thermodynamic stability,
prediction of poorly-behaving biologics is difficult, and searching for sequences with desired
properties is labour-intensive and time-consuming. Here we show that an assay in the
periplasm of E. coli linking aggregation directly to antibiotic resistance acts as a sensor for the
innate (un-accelerated) aggregation of antibody fragments. Using this assay as a directed
evolution screen, we demonstrate the generation of aggregation resistant scFv sequences
when reformatted as IgGs. This powerful tool can thus screen and evolve ‘manufacturable’
biopharmaceuticals early in industrial development. By comparing the mutational profiles of
three different immunoglobulin scaffolds, we show the applicability of this method to
investigate protein aggregation mechanisms important to both industrial manufacture and
amyloid disease.
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Over the last 30 years, recombinant antibodies haveemerged as highly effective therapeutics1,2. Antibody-based medicines now comprise over half of first-time
approvals3, and seven of the ten highest grossing pharmaceuticals
in 2018 were based on antibodies or antibody-like scaffolds4. This
success, and the development of more sophisticated therapeutic
strategies based on antibody scaffolds that incorporate multi-
dentate interactions and/or effector functions5,6, is partly due to
the ability to readily generate high affinity candidate therapeutics
using hybridoma or phage display platforms7–9. While the
structural and biophysical properties of antibodies and other
protein scaffolds allow the formation of highly avid complexes,
the inherent metastability of proteins can result in local or global
unfolding that can lead to inactivation and/or protein aggrega-
tion. Here, we define aggregates as all species with higher mole-
cular weight than the soluble monomer. This encompasses stable
or transient interactions between ordered or disordered states.
Aggregation can also be triggered by native-state interactions
(colloidal or hydrophobic). As proteins are subjected to various
stresses during manufacturing that increase the risk of protein
misfolding and aggregation10, overcoming aggregation (which
may be associated with low protein stability and/or low solubility)
is a major hurdle in the development of biopharmaceuticals.
Aggregation compromises the quality, stability, and even safety of
a drug product11–13, yet our ability to identify ‘manufacturable’
candidates with long-term stability during lead isolation and
optimisation remains challenging. Similarly, our ability to predict
the in vivo aggregation propensity of intrinsically disordered
proteins and globular proteins associated with protein aggrega-
tion diseases14 and how subtle sequence changes alter aggregation
in vivo/in vitro are also currently beyond our means. One reason
for this is a lack of structural and molecular understanding of the
mechanism(s) of the initiation and propagation of protein
aggregation, making development of a suitable screen difficult11.
For biopharmaceuticals, the relationship between different
‘developability’ assays has recently been delineated15. However,
the ability of these assays to predict manufacturability and long-
term stability remains poor16, due to lack of a known key quality
attribute for aggregation resistance.
A variety of in silico tools have recently been developed to
identify aggregation-prone sequences to guide rational design of
proteins with enhanced properties17–22, for example, by identi-
fying regions of poor solubility18,23 in the primary sequence or
three dimensional structure of a protein. While prediction of
sequences with high aggregation propensity19,24 or low
solubility18,22 is possible, predicting which of these aggregation-
prone regions (APRs) will become exposed (or sequestered) by
protein folding or unfolding events remains a significant chal-
lenge. Such complexity is highlighted by recent work on Tau, an
intrinsically disordered protein whose aggregation is linked to
neurodegenerative disease25,26. Molecular dynamics simulation is
an attractive option to identify such APRs27, but the necessity of a
structural model, length of computational time, the need for a
greater understanding of the conformational fluctuations that
trigger aggregation, and the availability of suitable force-fields to
replicate the stresses found in manufacturing make this approach
challenging.
In principle, directed evolution methods using phage, ribo-
some, or yeast display are powerful approaches capable of
investigating the effects of sequence changes on protein aggre-
gation. For example, biopharmaceutical model proteins have been
generated, a priori, with enhanced soluble expression28, ther-
modynamic stability29 or resistance to heat- or acid-induced
aggregation30,31. As aggregation can occur by a variety of
mechanisms including partial unfolding and homo- or hetero-
typic interactions in the native state, no singular property drives
aggregation. Consequently, development of a suitable screen to
enable the selection and optimisation of biopharmaceuticals for
resistance to innate aggregation by directed evolution has not
been possible. We have previously developed a tripartite β-
lactamase enzyme assay (TPBLA) (Fig. 1a, b) that allows the
identification and ranking of aggregation-prone peptides,
including the Alzheimer’s peptide (Aβ40/42) and islet amyloid
polypeptide (IAPP)32. In this assay, the test protein is fused in-
frame between the two domains of the E. coli periplasmic enzyme
β-lactamase (βLa, Fig. 1a, b). This assay thus directly links the
aggregation-propensity of the test protein to the susceptibility of
the bacterium to β-lactam antibiotics32. Importantly, by relying
solely on the innate aggregation propensity of the protein of
interest, the screen does not use arbitrary methods to destabilise
proteins (e.g. heat and chemical denaturation33) that may not
reflect the inherent dynamics of the test protein relevant to
aggregation during biomanufacture or in disease32,34.
Here, using both therapeutically relevant proteins and proteins
involved in aggregation disease as examples, we show that the
TPBLA can be used to assess the aggregation propensity of a
variety of protein structural scaffolds, including scFv fragments
from two monoclonal antibodies (mAbs) that differ by just three
amino acids in their VH domains, but which have fundamentally
different aggregation properties35. We then show that the TPBLA
can be used as a screen for directed evolution experiments to
select for sequences that are aggregation-resistant. Importantly,
the approach does not require any structural knowledge or prior
biophysical information about the protein of interest, and can be
used to reveal residues that modulate aggregation that could not
be predicted a priori using currently available algorithms. At a
fundamental level, the ability to detect multiple aggregation
liabilities simultaneously enables both spatially clustered and
more subtle pair-wise interactions that dictate aggregation to be
identified, allowing the delineation of aggregation hotspots in
both industrially-relevant and medically-important proteins. In
addition, identifying large numbers of sequence variants that
endow protection from aggregation will empower the develop-
ment of algorithms better trained to predict aggregation of bio-
logics and other protein scaffolds. This will allow a greater
understanding of the relationship between sequence, solubility
and aggregation, the developability of promising biologic candi-
dates and the prediction of mutations that may cause protein
aggregation disease.
Results
Protein aggregation correlates with bacterial survival. The
TPBLA has been used previously to rank the aggregation pro-
pensity of intrinsically disordered proteins and two pairs of
globular proteins32: β2microglobulin and D76N (an aggregation-
prone natural sequence variant), and Dp47d, a single VH domain
nanobody and its non-aggregating counterpart Hel430. To
determine whether the assay is able to differentiate between
aggregating and non-aggregating sequences of therapeutically
relevant protein scaffolds, we compared the in vivo growth scores
(area under the antibiotic survival curve, Fig. 1c, d) of Dp47d and
its non-aggregation counterpart HEL4, alongside two other
aggregation-prone therapeutically relevant protein scaffolds:
granulocyte colony-stimulating factor (GCSF) (a 174 residue four
helical bundle protein whose poor soluble expression in E. coli
was improved 1000-fold (GCSF C3) by ribosome display and
three parallel selection pressures36), and the single chain variant
(scFv) of an IgG1 antibody, MEDI1912 (referred to here as
IgGWFL)35. This recombinant human monoclonal antibody is
specific for human nerve growth factor (NGF) and displayed
significant aggregation and poor in vivo behaviour which was
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rectified in a variant containing three substitutions in the com-
plementarity determining regions (CDRs) 1 (W35S and F36T,
IMGT numbering37,38, Supplementary Fig. 1) and 2 (L64T) of
VH, generating the variant referred to here as IgGSTT35. The
in vivo growth score of bacteria expressing each of these con-
structs was measured in a 48-well agar plate assay (Supplemen-
tary Fig. 2) over a range of ampicillin concentrations (0–140 µg
mL−1) (Fig. 1c). For each protein, in vivo growth scores for the
engineered variant with low aggregation (scFvSTT, GCSF C3 and
HEL4, Fig. 1d) (high in vivo growth score) is significantly
enhanced relative to its aggregation-prone counterpart (scFvWFL,
GCSF and Dp47d, Fig. 1d) (low in vivo growth score). These data
validate the ability of the TPBLA to distinguish aggregation-prone
proteins from their less aggregation-prone sequences over a range
of different protein scaffolds.
As the biopharmaceutical sector is currently dominated by
IgGs, and many next generation therapies will also be based on
this class of proteins or their derivatives, we focussed subsequent
work on scFvWFL and scFvSTT. To assess the ability of the
tripartite β-lactamase assay to differentiate between proteins with
small changes in sequence, and to determine which of the amino
acid substitutions (W35S, F36T or L64T) is responsible for the
improved behaviour, the survival curves and in vivo growth
scores for six variants that substituted W35S, F36T and L64T
either individually or in combination were measured. The results
showed that W35S largely endows aggregation resistance,
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Fig. 1 The tripartite β-lactamase assay. a The test protein (green) is inserted into a 28-residue glycine/serine-rich linker (grey) separating the two
domains of the E. coli enzyme TEM-1 β-lactamase (purple and pink). b Correct folding of the test protein in the E. coli periplasm enables the two halves of β-
lactamase to be brought into close proximity to form the functional enzyme active site that hydrolyses β-lactam antibiotics. c Antibiotic survival curve of
the maximal cell dilution allowing growth (MCDGROWTH) on solid medium over a range of ampicillin concentrations for bacteria expressing the
aggregation-prone scFvWFL within β-lactamase (blue) or the aggregation-resistant sequence scFvSTT (pink). d Calculating the area under the antibiotic
survival curves (blue and pink shaded area, c) yields a single value to compare the behaviour of the different sequences. Data are shown for three
aggregation-prone model therapeutic proteins (open bars) and their engineered aggregation-resistant counterparts (solid bars). Data represent mean
values ± s.e.m. (n= 4 biologically independent experiments). Asterisks denote significance: **p < 0.002, ****p < 0.0001 (two-sided t-test). Source data are
provided as a Source Data file.
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Fig. 2 Comparison of the aggregation of WFL and its sequence variants in
a scFv format in vivo and in an IgG1 format in vitro. Average in vivo
growth score (bars, with individual experimental data shown as points) for
scFvWFL and scFvSTT together with their six combinatorial variants.
Positions with the same amino acid as STT are highlighted in pink. Error
bars represent s.e.m. (n= 4 biologically independent experiments). These
data are overlaid with the HP-SEC retention times for the same variants
reformatted as an IgG1 (black dots). Source data are provided as a Source
Data file.
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followed by F36T, with L64T making little contribution (Fig. 2,
Supplementary Fig. 3). Importantly, this insight can be achieved
without the need to express and purify the proteins for
biophysical analysis.
In vivo scFv aggregation correlates with IgG1 aggregation. In
order to use the TPBLA as a mAb developability screen it is
essential that the minimal scFv constructs used in the assay yield
similar aggregation propensities when reformatted as a full-length
IgG. Consequently, each of the eight scFvs variants described
above (WFL, WFT, WTL, WTT, SFL, SFT, STL and STT) were
generated as IgG1 antibodies and their retention time on a high-
performance size exclusion chromatography (HP-SEC) column
was quantified (Fig. 2). HP-SEC is usually used in the bio-
pharmaceutical industry to assess aggregation by quantification of
monomer loss. As shown previously35, while IgGSTT has an elu-
tion time consistent with a monomeric IgG1 (∼8.5 min), IgGWFL
displays an asymmetric elution profile with a longer retention
time (∼14 min) than expected based on monomer mass even in
the presence of 125 mM arginine39. Consequently, the retention
time was used in this study to assess the non-specific interactions/
aggregation of this family of biologics. Overlaying the retention
times for all eight variants with the in vivo assay scores shows an
excellent correlation between an improvement in bacterial growth
and a decrease in column retention time (Fig. 2). The interface
between IgGWFL dimers, formed en route to larger aggregates, has
been shown previously (by chemical cross-linking and MS
mapping) to be mediated by contacts between the VH and VL
domains in different molecules35. Repeating these experiments
for scFvWFL and scFvSTT, using increasing concentrations of the
amine-specific cross-linker bis(sulfosuccinimydyl)suberate (BS3)
showed that the majority of scFvSTT (99%) remained monomeric,
whilst 45% of scFvWFL was incorporated into higher-order oli-
gomers (Supplementary Fig. 4a), consistent with both the TPBLA
and HP-SEC data. Analysis of the dimers formed in scFvWFL by
mass spectrometry showed inter-protein cross-links between
residues M0 (VH) and K66 (VL) and M0 (VH) and M0 (VH)
(IMGT numbering), consistent with those formed for IgGWFL
(Supplementary Figs. 4 and 5), confirming conservation of the
interactions formed in the initiating stages of aggregation.
Together, these results show that the TPBLA allows the rapid
assessment of the aggregation propensity of scFv fragments,
which are maintained when inserted into an IgG1 scaffold.
Evolving proteins with reduced aggregation propensity. Having
established that the TPBLA could be used in candidate selection,
we next sought to use the assay as a screen for directed evolution
in order to search for novel sequences able to ameliorate poor
developability for candidates with promising therapeutic activity
such as IgGWFL. To achieve this, genetic variation was introduced
into the gene encoding scFvWFL using error-prone PCR, before
inserting the resulting library of sequences into the β-lactamase
vector yielding a library of 1.3 × 106 mutants (Methods). The
DNA sequences of 57 variants in the naive library revealed an
average mutational frequency of 8 amino acid substitutions per
scFv. For screening, the plasmid DNA library of βLa-scFvWFL
variants (βLa-scFvWFL*) was transformed into E. coli SCS1 cells
and plated onto agar containing 80 µg mL−1 ampicillin. At this
antibiotic concentration, colonies should only grow if they
express βLa-scFvWFL variants that increase the expression of
soluble and functional β-lactamase, compared with wild-type
βLa-scFvWFL (refer to Fig. 1 c). From the 315 colonies that could
grow under this selection pressure, 185 variants were randomly
selected and their in vivo growth score was measured, together
with that of βLa-scFvWFL and βLa-scFvSTT. The resulting data
(Fig. 3a) showed that 181 of these 185 variants displayed
enhanced growth relative to WFL, with 12 having superior
growth to the rationally engineered aggregation-resistant STT. To
determine whether the in vivo growth score for these evolved
variants also correlates with reduced aggregation propensity
within an IgG1 scaffold, ten variants that spanned the rank order
were converted to IgG1 molecules for further analyses. Molecules
were selected sequentially across the rank (starting with 139, the
best performing variant) by calculating in vivo growth scores
separated by one standard deviation (s.d.) of the replicate error
(βla-scFvSTT n= 16, s.d.= 130). For each of these values, the
variant with the fewest substitutions relative to WFL was selected
for further analyses in IgG format. This identified eight variants
(11, 176, 59, 72, 126, 130, 16 and 139). Two further sequences (37
and 128) were selected for study as these were found to retain the
original WFL residues (W35, F36 and L64) yet had improved
in vivo growth score. The location and identity of each of the
substitutions for these variants are shown in Supplementary
Fig. 6. The aggregation propensity of these IgGs was then assessed
using HP-SEC. As with the rationally engineered variants
(Fig. 2a), a clear inverse correlation was observed between the
retention time on HP-SEC and the in vivo growth score: anti-
bodies with high in vivo growth scores exhibited shorter retention
times reflecting reduced interactions with the column matrix
(Fig. 3b). The aggregation properties of the ten evolved IgG
variants, together with IgGWFL and IgGSTT, were also measured
using AC-SINS (affinity-capture self-interaction nanoparticle
spectroscopy)40,41. This method identifies self-association by an
increase in the plasmon wavelength of gold nanoparticles upon
their clustering induced by self-association of antibodies immo-
bilised on their surface. Figure 3b shows an excellent direct cor-
relation between the magnitude of the red shift in AC-SINS with
the retention time by HP-SEC, adding further support to the
ability of the TPBLA to select for sequences with reduced ten-
dency to self-associate both as scFvs and as intact IgGs. Inter-
estingly, as the majority of the evolved variants displayed similar
thermal melting transitions to those observed for IgGWFL (56 and
73 °C, assessed by differential scanning fluorimetry, DSF), no
correlation was found between the aggregation propensity or the
in vivo growth score with thermal stability (Supplementary Fig. 7,
Supplementary Table 1).
The application of a single selection pressure may result in
increased aggregation-resistance at the expense of target affinity,
akin to affinity/stability trade-offs29. To assess this possibility,
IC50 values for the cognate antigen NGF35 were measured for
each of the ten evolved IgG variants by a competition binding
assay monitored by fluorescence, and the results compared with
IgGWFL, IgGSTT and MEDI578 (the parent antibody prior to
affinity maturation into MEDI191235 (Fig. 3c, Supplementary
Table 2)). The results showed that all of the evolved antibodies
maintain higher affinity to NGF than MEDI578, demonstrating
that all variants retain functional activity, with no correlation
between IC50 and in vivo growth score values (Supplementary
Fig. 8)35.
Mutation hotspots identify localised frustration within IgGs.
Analysis of the mutational frequency of individual residues within
the aggregation-resistant scFv sequences enabled a protein-
specific profile of residues that might contribute to aggregation
to be generated. Such ‘hotspot’ residues represent ideal targets for
mutation to improve bioprocessability of the sequence when
reformatted as an IgG, or to improve soluble expression of pro-
teins more generally. The mutational-frequency profile across the
VH and VL domains of the library (βLa-scFvWFL*) was con-
structed from the sequences of all 315 variants that grew under
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the selection pressure of 80 µg mL−1 ampicillin (Fig. 4a). This
analysis revealed 12 hotspot residues with a mutational frequency
significantly higher (>2 s.d.) than the mean (labelled by residue in
Fig. 4a). Nine of these residues, which are all hydrophobic or
aromatic, lie in the VH domain, and are clustered in the CDR
regions: F30, W35, F36 (CDR1), I56, I57, I59 and F62 (CDR2),
and I110 and L112c (IMGT numbering) (CDR3). The remaining
three hotspot residues lie in the VL domain (K18, N57 and I71).
The chemical identity of the most frequently selected residue, and
whether a particular amino acid residue is enriched relative to all
other residues possible via a single-base-pair change, was also
assessed (Table 1). Interestingly, the hotspot residues in VH (most
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Fig. 3 In vivo growth score of evolved βLa-scFvWFL variants and the aggregation propensity and target affinity of ten selected variants in IgG1 format.
a Ranked in vivo growth score of 185 variants (Inset shows error for controls βLa-scFvWFL and βLa-scFvSTT, data represent mean values ± s.d. (n= 15
biological repeats)). Ten variants across the rank (11, 176, 37, 59, 128, 72, 126, 130, 16 and 139) were selected and reformatted as full-length IgG1s for
biophysical analysis. b HP-SEC retention time (green dots, longer times indicate greater interaction with column matrix) and AC-SINS (purple triangles,
larger plasmon shifts correlate with greater self-association. n= 3 technical repeats. Note: error bars smaller than symbols (mean values)) of the ten
selected variants in IgG1 format. These data correlate inversely with in vivo growth score (grey bars represent mean values, error bars represent s.e.m. n=
3 technical repeats). c Data used to calculate the IC50 values of binding of the ten evolved variants in IgG1 format to NGF determined using a homogeneous
time-resolved fluorescence assay (HTRF). Data represent mean values ± s.d. (n= 3 technical repeats). Source data are provided as a Source Data file.
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of which are solvent exposed and hydrophobic) tended to be
substituted with more hydrophilic residues (Ser and Thr), while
the hotspot residues in the VL domain which were initially
charged (K18), hydrophilic (N57) or hydrophobic (I71) were
substituted with polar or other charged amino acids.
In order to understand whether the mutation frequency profile
for scFvWFL was specific for this scFv sequence, or simply
reflected innate frustration of the Ig-fold itself, we performed the
same directed evolution screen on two other IgG scaffolds: a
second industrially-derived scaffold (a scFv variant of the anti-
LINGO-1 mAb, Li3342) and a λV6-57 VL domain (JTO) isolated
from a patient with multiple myeloma with tubular cast
nephropathy43 (Supplementary Figs. 9a and b). The resultant
mutational-frequency profiles (Fig. 4b and c), from 140 and 75
DNA sequences, respectively, contrast markedly and also are
distinct to that for scFvWFL (Fig. 4a). For JTO, the TPBLA reveals
sequence-wide frustration, with clusters of frequently mutated
residues (>2σ) observed both within, or directly flanking, its
CDRs, as well as in the framework region (notably involving
residues 19–21 and 51–54 and the C-terminal region). In accord
with recent work by Rennella et al.44, this apparently non-specific
profile may reflect the fact that the aggregation of this domain is
driven from the unfolded state by interactions between APRs
throughout the structure. In this case, the TBPLA may select for
sequences with both decreased aggregation propensity and
increased local or global thermodynamic stability (which
decreases the population/lifetime of solvent exposed APRs). In
light of this, the most frequently mutated hotspot was found in
β-strand B (residues 19–21, Fig. 4c), highlighting this region as a
particularly important driver of aggregation as reported
previously44.
By contrast, both to this sequence-wide effect and the relatively
localised profile for scFvWFL, scFvLi33 showed minimal frustration.
Only three residues, F30 and I36 in VH (most commonly
substituted with S and T, respectively) and L53 in VL (most
commonly substituted with P), exhibited substitution frequencies
significantly greater (>2 s.d.) higher than the mean. The
difference in the profiles of scFvWFL and scFvLi33 is remarkable,
given the similarity of their framework regions (66.5% similarity
and 48.2% identity (Supplementary Fig. 10)), but may be expected
as their poor developability has been ascribed to different
mechanisms: aberrant CDR-CDR (WFL)35 and CDR-constant
region (Li33)42 interactions. As the TPBLA employs scFvs, it
cannot detect aberrant CDR- constant region interactions, and
given that Li33’s solubility depends critically on the type of IgG
scaffold42, we hypothesised that the dominant evolutionary
pressure in the TPBLA for this sequence may be thermodynamic
stability, rather than its innate aggregation propensity, as was also
previously observed for the soluble globular protein Im7 using
this assay34. To test this hypothesis, the scFv sequences for Li33,
Li33I36T, Li33Y88D and Li33L53P (the single point variants with the
highest in vivo growth score, Supplementary Fig. 9) were grafted
into an IgG1 scaffold. Surprisingly, no significant changes in
thermal stability were detected between the wild-type and evolved
Li33I36T, Li33Y88D variants, whilst a single broad transition was
observed for Li33L53P (Supplementary Fig. 11, Supplementary
Table 1). Instead, small but significant reductions in self-
association monitored by AC-SINS (Supplementary Fig. 12a)
over wild-type Li33 were observed for I36T and L53P. In
addition, L53P and Y88D showed increased solubility relative to
wild-type as assessed by a polyethylene glycol (PEG) precipitation
assay (Supplementary Fig. 12b). These data suggest that the
TPBLA is able to identify (and resolve) specific problematic
residues between proteins with identical topologies and highly
similar sequences and does not simply identify scFvs with
increased thermal stability. Together, these results demonstrate
the power of the TPBLA to develop new understanding of the
molecular determinants of aggregation associated with proteins of
relevance for bioprocessing, as well as those associated with
protein misfolding diseases.
Comparison of mutational hotspots with in silico predictions.
Several in silico approaches have been developed to identify
residues/sequences with poor solubility (e.g. structurally corrected
Camsol18), or high aggregation propensity (e.g. Aggregscan3D45
and SAP19). Comparison of the location of the sequence hotspots
identified here for scFvWFL by directed evolution, with those
predicted based on these algorithms are shown in Fig. 5a, b,
Supplementary Fig. 13 and Supplementary Table 3. The results
portray the complexity in determining protein aggregation based
on predictions alone. Each algorithm detected at least one of the
insoluble or aggregation-prone residues in CDR1 and CDR2 of
scFvWFL that form the large hydrophobic patch shown pre-
viously35, and recapitulated here for scFvWFL, to be involved in
the aggregation interface. The identity of the residues involved,
Table 1 Summary of the 12 most frequently substituted residues after directed evolution of the scFvWFL* library.
Residue RSAa Most frequently
observed aa
substitution
Mutation frequency
of most often
observed mutation
Expected frequency
of most often
observed mutationb
Amino acid
substitutions
observedc,d
Available residues
with single DNA
base changed
F30 0.07 S 0.81 0.41 SLPV IVLFCSY
W35 0.63 R 0.93 0.90 RG LCGSR
F36 0.66 S 0.60 0.41 SL(VP)(IT) IVLFCSY
I56 0.09 V 0.50 0.43 VT(LF) IVLFMTSN
I57 0.01 T 0.66 0.44 TNVA IVLFMTSN
I59 0.44 T 0.60 0.43 TNVF IVLFMTSN
F62 0.45 S 0.60 0.43 SLY IVLFCSY
I110 0.19 T 0.82 0.43 TV(LFM) IVLFMTSN
L112c 0.65 P 1.00 0.83 P IVLFPHR
K18LC 0.81 E 0.52 0.44 ERNQ ITEQNKR
N57LC 0.18 D 0.73 0.43 DSG ITSYHDNK
I71LC 0.24 T 0.62 0.43 TVN IVLFMTSN
aRSA= relative surface area (0= completely buried residue, 1=maximally solvent exposed residue (see Methods)).
bExpected frequency calculated using the mutational bias found in the naive library.
cResidues are listed in decreasing mutational frequency with brackets indicating residues with equal frequency of mutation. Substitutions shown in bold are due to two base-pair changes in the
DNA codon.
dAmino acids are listed in decreasing hydrophobicity (left to right) using the Kyte-Doolittle scale57.
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however, varied between algorithms. SAP and Aggrescan3D also
identified a third hotspot-cluster in CDR3. In addition, each in
silico method highlighted additional residues in VH that were not
identified by directed evolution, and no in silico method identi-
fied any of the hotspot residues in VL. In total the three algo-
rithms highlighted 26 residues as potential positions in which
aggregation could be suppressed by mutation, including eight of
the 12 most frequently mutated residues identified here by
directed evolution. However, only three residues are flagged by all
three algorithms (Supplementary Fig. 14).
Since the variants of scFvWFL generated by evolution each
contain several mutations (for example see Supplementary
Fig. 6b), the importance of individual amino acid substitutions
to the properties of the proteins remained unknown. To examine
the relative importance of each individual substitution and to
determine how these values relate to in silico predictions, the
in vivo growth score for βLa-scFvWFL* variants containing the
most common amino acid substitution in each of the 12 hotspot
residues was measured (Supplementary Fig. 15). While no single
substitution was found to match the in vivo growth score for STT
(690 ± 8 A.U.), F62S, a residue not mutated in rational design of
STT35, achieved 91% of this enhancement (643 ± 27 A.U.). By
contrast, F36, which was mutated to Thr in the rational design of
IgGSTT, only achieved 15% of the enhancement when mutated to
Ser in our assay (scores for WFL and F36S were 172 ± 53 A.U.
and 250 ± 9 A.U., respectively). Quantifying the effect of single
substitutions also did not improve the correlation with in silico
methods. For example, only three residues (F36, I59 and F62) are
flagged by all three computational methods (Supplementary
Fig. 14), yet these vary considerably in their in vivo growth score
(ranked 10th, 5th and 1st, respectively (Supplementary Fig. 15)).
Overall, while there is some agreement between in silico
approaches and the TPBLA, the identity of the problematic
residues determined experimentally and predicted computation-
ally varies considerably (Supplementary Table 3). Hence,
identification of the key residues to target by rational engineering
would be difficult using a multi-algorithm approach, highlighting
the power of using evolution to find solutions to the problem of
aggregation.
Discussion
Split β-lactamase assays have been used previously as a proxy for
several characteristics including protein–protein interactions46, a
marker for gene expression47, and for selecting open reading
frames48. These assays exploit β-lactamase’s stability, the presence
of permissive grafting sites in its structure, and the potential for
high throughput screening via colorimetric assays. Here, we have
shown the ability of the versatile tripartite β-lactamase
platform32,34,49 to distinguish aggregation-prone variants of
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Fig. 5 Comparison of computational predictors of aggregation with the evolved mutational hotspots for WFL. a Comparison of evolution hotspots for
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aggregation-prone regions are shown on a surface model of the protein (created from PDB 5JZ735) in red and blue, respectively. b Computational
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diverse biopharmaceutically-relevant protein scaffolds from their
more aggregation-resilient counterparts. In contrast with other
in vivo systems for studying protein aggregation50,51, this assay
has the advantage that fusion proteins are expressed in the
periplasm of E. coli, allowing the formation of disulfide bonds,
such as those found in IgGs and their derivatives. Most impor-
tantly, no perturbant such as increased temperature, pH or che-
mical denaturant is used to accelerate aggregation, allowing
identification of sequence characteristics that trigger innate
(unaccelerated) aggregation pathways. Furthermore, this assay
has broad utility as it is agnostic to the underlying mechanism of
aggregation (e.g. unstructured peptides with a high propensity for
amyloid formation as well as for globular proteins that self-
assemble through a variety of mechanisms). We have shown that
the aggregation propensity driven by the self-association of
IgGWFL is largely determined by the Fv region, as IgG1 and scFv
homologues yield the same rank order of aggregation propensity
judged both within the βLa fusion, and as purified IgGs (Fig. 2a).
As scFvs are commonly reformatted into IgG scaffolds, and scFv
formats are frequently used in phage or other display systems, the
assay could readily be integrated into the development pipeline to
identify developable sequences directly after discovery and affi-
nity maturation. The assay is amenable to any protein displayed
as a single chain, and hence could be used to optimise a wide
variety of biologics, including dAbs, scFabs, scFc (with co-
expression of these allowing the detection of Fab:Fc interactions)
and bispecifics (in scFv format) all of which are poorly char-
acterised in terms of developability relative to platform IgGs.
We have also shown here the power of the TPBLA combined
with directed evolution to rectify problematic sequences, and to
identify mutational hotspots that limit protein behaviour (due to
a variety of mechanisms) in both the variable and framework
regions. Here, we took a previously characterised IgG with known
development issues35, IgGWFL, and engineered new sequences
(Fig. 3a) with reduced self-association as measured by HP-SEC
and AC-SINS (Fig. 3b, c). It is notable that the sequence of the
rationally engineered IgGSTT was not isolated during screening.
The best performing evolved variant involved substitution of only
one of these residues (F36), demonstrating the advantages of
directed evolution and selection over rational approaches.
Screening a randomised scFv library of a second industrially-
derived sequence (Li33) identified substitutions in different hot-
spots. These substitutions were found to improve solubility in the
context of an IgG1 scaffold (Supplementary Fig. 12), demon-
strating its broad utility. In this regard, it is intriguing that the
mutational-frequency profile for the ‘synthetically-derived’
sequences of WFL and Li33 differ significantly from one opti-
mised for humoral immunity, examined here using JTO. A
complex mutational profile is observed for the latter, which may
reflect both the selective pressure to increase thermodynamic
stability and minimise APRs (whose identity found here using the
TPBLA correlates with experimental results and in silico pre-
dictions44). By contrast, the majority of hotspot residues identi-
fied for both scFvWFL and scFvLi33 are located in, or close to, the
CDRs. Given the importance of the CDRs in determining epitope
binding affinity, this is unsurprising and, at first glance, may
appear to be problematic for the maintenance of a successful
candidate profile. We have shown here, however, that binding
affinity can be maintained concomitantly with a significant
improvement in aggregation performance, at least for variants of
IgGWFL, presumably because only a subset of CDR residues are
directly involved in epitope binding35. Indeed, the crystal struc-
ture of the scFv of the IgGMEDI578 (the parental sequence of
IgGWFL) in complex with its ligand35 shows direct interaction of
only 6 of the 16 residues in CDR1 and CDR2, with CDR3 making
13 out of a total of 22 contacts to NGF.
Despite the ability of the TPBLA to generate candidate
sequences with greatly improved properties, it remains challen-
ging to determine how the different amino acid substitutions
introduced actually ameliorate aggregation. This arises because
aggregation results from a complex interplay of properties that
includes kinetic and thermodynamic stability, the number and
position (solvent accessibility) of aggregation-prone regions, and
local dynamics that may expose those regions. Analysis of the
substitutions made here for scFvWFL in the context of their
location in the protein (Table 1) allows the cause of the liability to
be putatively assigned. For example, 10 of the 12 hotspot residues
found for scFvWFL are hydrophobic/aromatic in nature and all
were substituted with more hydrophilic residues, consistent with
the mechanism of aggregation suggested previously for this
protein35. In accordance with this hypothesis, three different
algorithms that predict solubility and aggregation propensity of
amino acid sequences within structured18 and dynamic protein
domains19,45, identify the same region. These algorithms, how-
ever, yield different predictions, confusing the choice of residues
to mutate in any rational approach to improve protein behaviour.
The ability of the TPBLA to quantify aggregation propensity in
the absence of protein purification engenders its use as a funda-
mental research tool. Firstly, it allows optimisation of protein
expression for experimentally intractable proteins (e.g.
aggregation-prone or insoluble proteins). Secondly, using the
TPBLA as a screen for deep mutational scanning52 would allow
areas of sequence frustration (i.e. destabilisation due to functional
constraints or aggregation propensity) to be mapped and their
underlying mechanisms of aggregation to be better understood,
enabling their modification using rational engineering approa-
ches. A fundamental understanding of biopharmaceutical aggre-
gation during manufacture and storage is still lacking more than
30 years since the first introduction of IgGs into the clinic. We
have shown here that the TPBLA is a powerful method by which
to identify (using the TPBLA alone), or re-engineer (using the
TPBLA as a directed evolution screen) inherently manufacturable
proteins. Combining the TBPLA with the approaches described
above may thus be of enormous practical benefit to create pro-
teins with improved behaviour, and when combined with evo-
lution methods, may be able to provide the mechanistic
understanding needed to apply a true quality-by-design approach
to biopharmaceutical discovery and development.
Methods
Construction of β-lactamase fusions. Synthetic DNA sequences (purchased from
Eurofins Genomics) encoding GCSF, scFvWFL and scFvLi33, and their variants, were
inserted in-frame into the 28-residue G/S linker (previously inserted between
residues 196 and 197 of TEM-1 β-lactamase34) in the pMB1-βla-linker plasmid via
a 5′ (XhoI) and 3′ (BamHI) restriction site. Ligation products were transformed
into E. coli SCS1 cells (Stratagene) and the cells grown on agar plates containing
10 µg mL−1 tetracycline. The identity of the resulting clones was verified by DNA
sequencing (DNA and amino-acid sequence of the βla-linker and the test protein
variants used are listed in Supplementary Tables 4 and 5).
In vivo growth assay. MCDGROWTH (maximal cell dilution allowing growth)
assays were performed in sterile 48-well LB agar plates (Greiner Bio-One, cat.
677102) prepared prior to the assay. Tetracycline (10 µg mL−1 final concentration)
and filter-sterilised L-arabinose (final concentration of 0.075% (w/v) for scFvWFL/
scFvLi33 or 0.1% (w/v) for JTO) were added to 100 mL of sterile 1.5 % (w/v) LB agar
cooled to <50 °C. Three hundred microlitres of this solution was added into each of
the first 6 wells (first row) of the 48-well plates. Ampicillin (10 mgmL−1 stock) was
then added to the LB agar stock to give the required concentration for the next
row of wells. This procedure was repeated until the plate contained 8 rows of
LB agar containing increasing concentrations of ampicillin. β-lactamase-test pro-
tein constructs were screened over an ampicillin range of either 0–140 μg mL−1
(20 μg mL−1 increments) or 0–280 µg mL−1 (40 µg mL−1 increments). Agar plates
were left to set in a sterile environment.
A single colony of fresh E. coli SCS1 cells (Stratagene) transformed with the
appropriate plasmid was used to inoculate 5 mL sterile LB containing 10 µg mL−1
tetracycline. Cultures were incubated overnight at 37 °C with shaking (200 rpm).
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One millilitre of overnight culture was used to inoculate 100 mL sterile LB
containing 10 µg mL−1 tetracycline and grown at 37 °C (shaking at 200 rpm) until
an OD600 of 0.6 was reached. Expression of the β-lactamase fusion construct was
induced by the addition of filter-sterilised arabinose at a final concentration of
0.075% (w/v) (scFvs) or 0.1% (w/v) (JTO). Cultures were incubated for a further 1
h then serially diluted 10-fold into sterile 170 mM NaCl solution. Three microlitres
of each dilution was then spotted onto the pre-prepared 48-well agar plates. The
plates were incubated at 37 °C for 18 h and the MCDGROWTH was determined for
each ampicillin concentration by visual inspection.
A single value from each MCDGROWTH assay, illustrative of the effect of each
scFv on bacterial growth, was calculated from the area under the MCDGROWTH
curves as a sum of the areas of 7 trapezia using Eq. (1), where Acurve is the total area
under the curve, and xi and yi are the x-axis and y-axis values at each concentration
of ampicillin.
Acurve ¼
X7
i¼1
yi þ yiþ1
2
´ xiþ1  xi
  ð1Þ
Construction and expression of IgGs. scFv variants chosen for further study were
reformatted into the TM-YTE IgG1 backbone by cloning eukaryote codon-
optimised VH and VL domains into human TM-YTE IgG1 heavy chain and light
chain expression vectors53. The plasmids were co-transfected into HEK293/EBNA
mammalian cells (Invitrogen, Catalog no. R620-07) for expression and IgG pro-
teins purified from the culture medium using Protein A chromatography.
High-performance size exclusion chromatography (HP-SEC). HP-SEC was
performed using an Agilent 1100 series HPLC fitted with a TSK SWXL HPLC
guard column (Tosoh Bioscience) and TSK-GEL G3000SWXL HPLC column
(Tosoh Bioscience). Fifty microlitres of IgG at 1 mgmL−1 in Dulbecco’s Phosphate
Buffered Saline (D-PBS) (Sigma-Aldrich) was injected at a flow rate of 1 mLmin−1
using 0.1 M sodium phosphate, 0.1 M sodium sulphate, pH 6.8 as the mobile-phase
buffer.
Chemical cross-linking. scFvs (15 µM) were dialysed into 100 mM sodium
phosphate buffer, pH 7.4 and cross-linked with a mixture (50:50) of d0-BS3 and d4-
BS3 (Thermo Scientific, UK) at different molar excesses: 50×, 100×, 200× and 500×.
The cross-linking reaction was left for 30 min at 25 °C before being quenched with
Tris.HCl, pH 8 (50 mM final concentration). The cross-linked and non-cross-
linked samples were then resolved using SDS-PAGE and the cross-linked dimer
bands, along with cross-linked and non-cross-linked monomer, were excised from
the gel for in-gel trypsin digestion. The gel pieces were subjected to three repeat
rounds of hydration and dehydration with 25 mM ammonium bicarbonate, pH 7.8
and 50% (v/v) acetonitrile/25 mM ammonium bicarbonate, respectively. Samples
were then treated with 10 mM DTT and the cysteine residues subsequently alky-
lated with 55 mM iodoacetamide. The gel pieces were dehydrated again using 50%
(v/v) acetonitrile/25 mM ammonium bicarbonate before being re-hydrated with a
0.1 µg/µL trypsin solution and incubated for 18 h at 37 °C. Digested peptides were
recovered from the gel by subjecting the gel pieces to four repeat rounds of
dehydration with 60% (v/v) acetonitrile/5% (v/v) formic acid. Extracted peptides
were then concentrated before LC-MS/MS analysis. Densitometry calculations were
performed using ImageJ.
LC-MS/MS analysis of extracted cross-linked peptides. Extracted peptides
were analysed on a nanoAcquity LC system connected on-line to a Synapt G2-Si
mass spectrometer (Waters Ltd., Wilmslow, UK). One microlitre of extracted
peptide samples were injected onto an Acquity M-Class column (C18, 75 µm × 150
mm) (Waters Ltd., Wilmslow, Manchester, UK) and subsequently separated by a
1–50% gradient elution of solvent B (0.1% (v/v) formic acid: acetonitrile) in solvent
A (0.1% (v/v) formic acid in water) over 60 min at a flow rate of 0.3 µL min−1. The
instrument was operated in positive ion mode using collision-induced dissociation
(CID) for fragmentation of selected ions. Data dependant MS/MS experiments
were conducted in the trap region of the instrument using a 1-s scan with the five
most intense ions being selected for fragmentation over a 350–2000m/z window.
Fragmentation of less abundant cross-linked ions was achieved through manual
inclusion in sequential acquisitions after analysis of the MS and MS/MS data. The
data were analysed using the MassLynx software (version 4.1) and StavroX (version
3.6.0.1).
Cross-linking data analysis. Data were imported into PEAKS studio (version 10)
and exported as MGF files, to then be imported and analysed by StavroX. Due to
the significantly lower levels of dimer formed for scFvSTT, the 200x cross-linked
sample was used while the 50x cross-linked sample was used for scFvWFL. The data
were searched against the protein sequences for scFvWFL and scFvSTT. StavroX
parameters used for searching were as follows: K and R protein cleavage sites (with
2 and 1 potential missed cleavages, respectively), fixed modification of C to B
(cysteine to carboxyamidomethylcysteine) and variable modifications of M to m
(methionine to oxidised methionine) with a maximum of two variable modifica-
tions per peptide. The non-deuterated and deuterated BS3 cross-linker was added
to StavroX, C8H10O2 (138.07 Da) and C8H6D4O2 (142.09 Da), respectively. To
include all potential cross-links, the site specificity was set as lysine (K) for peptide
1 and to lysine (K), serine (S), threonine (T) or tyrosine (Y) residues, as well as
including the N-terminal amine 54 for peptide 2. Mass tolerances were set as 3.0
ppm for the precursor ions and 0.8 Da for fragment ions with mass limits of
200–8000 Da. Low-precise scoring was used with an false detection rate cut-off of
5% and a score cut-off of 10. A decoy database was generated by shuffling the
sequence while keeping the protease sites.
Manual data validation was achieved using a comparative approach searching
for unique peptides from the digested dimer bands. Cross-linked peptides were
readily identified from the doublet peak (Δ4 Da) formed by use of a deuterated and
non-deuterated cross-linker.
DNA library synthesis. The Diversify PCR Random Mutagenesis Kit (Takara) was
used to synthesise a scFv megaprimer (error rate of 8.1 (WFL), 2.7 (Li33) or 5.8
(JTO) mutations per 1000 bp), using forward (5ʹ-GTGGTGGTGGCTCGA) and
reverse (5ʹ-AACCGCTCCCGGATC) primers that anneal to the Gly/Ser linker
regions up- and down-stream of the scFv sequence. The product was purified on a
1% (w/v) agarose gel and the desired band was excised and purified using Qiagen
Gel Extraction Kit, according to the manufacturer’s instructions. To prevent
expression of wild-type βLa-scFvWFL after ligation, a ‘stop template’ plasmid was
created. To this end, two stop codons were inserted into β-lactamase (amino acid
positions 109 & 110, Supplementary Table 6) in the pMB1-βLa-scFvWFL plasmid
using the Q5 Site-Directed Mutagenesis Kit (NEB). A ten-fold excess of scFv
megaprimer was added to the βLa-scFvWFL stop template and splicing performed
using the QuikChange Lightning Site-Directed Mutagenesis Kit (Agilent). Two
microlitres DpnI was then added to each reaction (1 h, 37 °C) to remove template
DNA. The product was purified using Qiagen PCR Purification Kit and 2 µL was
used to transform TG1 Electrocompetent cells (Lucigen) by electroporation (2.5 kV
field strength, 335Ω resistance and 15 µF capacitance). Following recovery, cells
were plated onto pre-prepared LB bioassay agar plates containing 10 μg mL−1
tetracycline and incubated overnight at 37 °C.
Single colonies were picked for sequence analysis before the remaining colonies
were removed from the bioassay plates by addition of 10 mL LB medium and
scraping off. The culture was centrifuged (10 min, 5000 × g) before DNA extraction
using the Qiagen Midiprep Kit, according to the manufacturer’s instructions.
Evolution assay. Directed evolution bioassay assay plates were prepared con-
taining 2.5% (w/v) LB, 1.5% (w/v) agar, 10 µg mL−1 tetracycline, 0.075% (scFvs) or
0.1% (JTO) (w/v) arabinose and either 80 µg mL−1 (WFL) or 140 µg mL−1 (Li33
and JTO) ampicillin. SCS1 Supercompetent Cells (Agilent) were thawed on ice for
10 min and 50 µL cells transferred to a 14 mL round-bottomed transformation
tube. Two microlitres of the prepared library plasmid DNA (100 ng µL−1) was
added to the cells and incubated on ice for 30 min before heat shocking at 42 °C for
45 s. After 5 min incubation on ice, 950 µL SOC medium was added to cells and
incubated (37 °C, 200 rpm) for 1 h. Three millilitres SOC medium was then added
to the cells along with 10 µg mL−1 tetracycline. Cells were incubated for 4 h and β-
lactamase expression then induced with 0.075 % (w/v) arabinose. Cells were then
incubated (37 °C, 200 rpm) for 1 h. The culture was spread onto the prepared assay
plates and incubated overnight at 37 °C.
Affinity-capture self-interaction nanoparticle spectroscopy (AC-SINS). Affi-
niPure goat anti-human IgG Fcγ Fragment specific (IgGα-Fc) and ChromePure
Goat IgG, whole molecule (IgGWHOLE) (Jackson ImmunoResearch) were buffer
exchanged into 20 mM potassium acetate, pH 4.3 and diluted to 0.4 mg mL−1.
Nine millilitres of citrate-stabilised 20 nm gold nanoparticles (Expedeon) were
incubated with 600 µL IgGα-Fc and 400 µL IgGWHOLE for 2 h at room temperature.
Nanoparticles were blocked with 0.1 µM 2000 MW thiolated PEG (Sigma-Aldrich)
at room temperature for 1–2 h. Nanoparticles were concentrated to 800 µL in
siliconised Eppendorf tubes (VWR) and stored at 4 °C. Forty-five microlitres of 50
µg mL−1 antibody samples were mixed with 5 µL nanoparticle solution and
incubated at room temperature for 30 min. The mixture was transferred to a 384-
well polystyrene UV transparent plate (Thermo Scientific), and the absorbance
read from 400 to 700 nm in 1-nm increments. The maximum absorbance was
determined (the plasmon wavelength) and the redshift in plasmon wavelength
compared with nanoparticles in the absence of antibodies was then calculated by
subtracting one from the other.
Epitope competition assay. The relative affinity of the IgGWFL variants for NGF
was established using a homogeneous time-resolved fluorescence (HTRF) epitope
competition assay. The assay determines relative affinity by measuring the
reduction in binding of biotinylated NGF (R&D Systems (256-GF, biotinylated in-
house)) to DyLight650-labelled IgGWFL in the presence of increasing concentra-
tions of test IgG. Binding of DyLight650-labelled IgGWFL to biotinylated NGF is
detected by FRET between streptavidin Europium cryptate (CisBio), which binds
biotinylated NGF and the DyLight650 conjugated to the IgG. Fluorescence was
measured on a PerkinElmer EnVision plate reader with the following settings: 100
flashes, delay 70, cycle 2000, Excitation UV2 (TRF) 320 nm, Emission APC 665
(Bandwidth 7.5 nm), Emission Rhodamine 590 (Bandwidth 20 nm), mirror D400/
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630. The HTRF ratio is calculated by Eq. (2) and the %DELTA F is calculated by
Eq. (3):
665 nm emission
590 nm emission
´ 10; 000 ð2Þ
ðSample ratio negative control ratioÞ
Negative control ratio
´ 100 ð3Þ
Differential scanning fluorimetry. Twenty microlitres of 0.52 mgmL−1 antibody
solution in PBS was added to a white PCR plate (BioRad). SYPRO Orange protein
gel stain (5000× stock, Invitrogen) was diluted to 40× in distilled H2O prior to
addition of 5 µL to each well. The plate was sealed, and melt curves obtained on a
BioRad CFX96 Real-Time PCR system (20–95 °C, increments of 0.2 °C per min and
hold time of 10 s) by measuring fluorescence intensities using the FRET channel
with excitation from 450 to 490 nm and detection from 560 to 580 nm.
Relative surface accessibility (RSA). RSA values were calculated by taking the
absolute solvent accessible surface area for the residue in the model of the structure
of scFvWFL (created by mutating PDB 5J7Z35 using Pymol 2.1.0) and dividing it by
the maximum possible area for the amino acid type as described by Miller et al.54.
Poly(ethylene glycol) (PEG) precipitation assay. A 40% (w/v) PEG 10,000
(Sigma) solution was prepared in PBS and corrected to a pH of 7.0. PEG solution,
PBS and 20 µL of IgG stock solution were combined to achieve a PEG con-
centration range of 0–10% (w/v) and final IgG concentration of 0.5 mg mL−1 in a
96-well plate in triplicate. Plates were sealed with adhesive sealing film and incu-
bated at 4 °C for 24 h. After incubation, samples were thoroughly mixed in their
respective wells before 2 µL of each sample was transferred to a Lunatic plate for
turbidity measurement at 500 nm on a Lunatic (Unchained Labs). Turbidity of
buffer only controls was subtracted from final readings.
In silico aggregation predictors. A model of the structure of scFvWFL (described
above) was used. The webserver for CamSol18 was used to generate a structurally
corrected profile at pH 7 with a 10 Å patch radius to identify soluble and insoluble
amino acids located at http://www-vendruscolo.ch.cam.ac.uk/camsolmethod.html.
Aggrescan3D 2.045 server was used to predict aggregation propensity located at
http://biocomp.chem.uw.edu.pl/A3D2/. Predictions were made in dynamic mode
with a 10 Å radius, and stability calculation option was selected, using FoldX55 to
optimise input structure. Spatial aggregation propensity (SAP) calculations were
performed using CHARMM56 simulations and method described by Chennam-
setty et al.19 using a 10 Å radius.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The datasets generated during the current study are available in the University of Leeds
data repository (https://doi.org/10.5518/739) and the Source Data file. The source data
underlying Figs. 1c, 2, 3, 4 and 5 and Supplementary Figs. 3, 7, 9, 11, 12 and 15 are
provided as a Source Data file. All other relevant data are available from the authors upon
reasonable request.
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